Pure Global
NCT06405243

Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients

The Combination of Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients
Beni-Suef University·Phase 3·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Polycystic Ovary Syndrome
Drug/Device/Intervention
Myoinositol
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Beni-Suef University
Location
Banī Suwayf,Banī Suwayf, Egypt
Timeline & enrollment
Phase
Phase 3
Start date
Jun 30, 2024
End date
Dec 31, 2024
Enrollment
100 participants
Primary outcome

ovulation

Summary

The aim of the study is to compare and assess the efficacy of combined letrozole with
 myoinositol, chromium, or L-arginine in infertile women with PCOS. This study will help in
 the investigation of alternative therapeutic modalities for fertility improvement in
 polycystic ovarian syndrome

ICD-10 classifications
Polycystic ovarian syndromeOvarian dysfunction, unspecifiedOvarian dysfunctionOther ovarian dysfunctionNeoplasm of uncertain or unknown behaviour: Ovary
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06405243
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06405243 through Pure Global AI's free database. This Phase 3 trial is sponsored by Beni-Suef University and is currently Not yet recruiting. The study focuses on Polycystic Ovary Syndrome. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.